PFG Investments LLC Grows Stock Position in Biosig Technologies, Inc. (NASDAQ:BSGM)

PFG Investments LLC boosted its position in shares of Biosig Technologies, Inc. (NASDAQ:BSGM) by 43.5% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 158,286 shares of the company’s stock after buying an additional 48,000 shares during the quarter. PFG Investments LLC’s holdings in Biosig Technologies were worth $95,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Millennium Management LLC bought a new stake in shares of Biosig Technologies in the 4th quarter worth about $228,000. Geode Capital Management LLC bought a new stake in Biosig Technologies in the fourth quarter worth about $143,000. Legacy Investment Solutions LLC purchased a new position in shares of Biosig Technologies during the fourth quarter valued at approximately $5,369,000. Finally, Integrity Wealth Advisors Inc. bought a new position in shares of Biosig Technologies during the fourth quarter valued at approximately $61,000. Institutional investors own 7.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets raised their price target on Biosig Technologies from $2.50 to $10.00 and gave the stock a “buy” rating in a research note on Friday, June 6th.

Biosig Technologies Trading Up 5.1%

Shares of Biosig Technologies stock opened at $8.51 on Friday. The firm’s 50-day moving average is $4.14 and its two-hundred day moving average is $2.07. Biosig Technologies, Inc. has a 1 year low of $0.23 and a 1 year high of $8.80.

Biosig Technologies (NASDAQ:BSGM) last released its quarterly earnings data on Monday, May 19th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.09). Equities analysts expect that Biosig Technologies, Inc. will post -0.88 EPS for the current fiscal year.

About Biosig Technologies

BioSig Technologies, Inc, together with its subsidiaries, a medical device company, engages in development and commercialization of advanced digital signal processing technology platform for the treatment of cardiovascular arrhythmias in the United States. It offers PURE EP system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures.